Stat1 is an inhibitor of Ras-MAPK signaling and Rho small GTPase expression with implications in the transcriptional signature of Ras transformed cells

Cell Cycle

Volumn 8, Issue 13, 2009, Pages 2070-2079

  Wang, Shuo ^a   Koromilas, Antonis E ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Gene expression; MAPK signaling; Protein phosphorylation; Ras transformation; Rho GTPsases; Stat proteins

Indexed keywords

GUANOSINE TRIPHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN CDC42; RAC1 PROTEIN; RAS PROTEIN; RHO FACTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN;

ARTICLE; CELL ADHESION; CELL CYCLE REGULATION; CELL TRANSFORMATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 67650538799     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.13.8891     Document Type: Article

References (104)

1. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3:651-662
2. Yu H, Jove R. The stats of cancer-new molecular targets come of age. Nat Rev Cancer 2004; 4:97-105. (Pubitemid 38198738)
3. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95:7556-7561 (Pubitemid 28293291)
4. Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE Jr. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA 1996; 93:7673-7678 (Pubitemid 26277095)
5. Chin YE, Kitagawa M, Kuida K, Flavell RA, Fu XY. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 1997; 17:5328-5337 (Pubitemid 27357631)
6. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996; 272:719-722 (Pubitemid 26152783)
7. Kumar A, Commane M, Flickinger TW, Horvath CM, Stark GR. Defective TNFalpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science 1997; 278:1630-1632 (Pubitemid 27516283)
8. Kovacic B, Stoiber D, Moriggl R, Weisz E, Ott RG, Kreibich R, et al. STAT1 acts as a tumor promoter for leukemia development. Cancer Cell 2006; 10:77-87.
9. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell 1999; 98:295-303.
10. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE Jr. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998; 18:2553-2558 (Pubitemid 28183425)
11. Zhang Y, Turkson J, Carter-Su C, Smithgall T, Levitzki A, Kraker A, et al. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem 2000; 275:24935-24944 (Pubitemid 30626601)
12. Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, et al. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol 1999; 19:7519-7528 (Pubitemid 29493415)
13. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10:48-54. (Pubitemid 38524698)
14. de la Inglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev 2008; 22:449-462 (Pubitemid 351272753)
15. Levy DE, Gilliland DG. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 2000; 19:2505-2510 (Pubitemid 30339206)
16. Tan SH, Nevalainen MT. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer 2008; 15:367-390 (Pubitemid 351880829)
17. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002; 109:1139-1142
18. Wang S, Raven JF, Durbin JE, Koromilas AE. Stat1 phosphorylation determines Ras oncogenicity by regulating p27 kip1. PLoS ONE 2008; 3:3476.
19. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK JNK, and p38 protein kinases. Science 2002; 298:1911-1912 (Pubitemid 35425238)
20. de Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 1997; 14:623-625 (Pubitemid 27090966)
21. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501. (Pubitemid 37328931)
22. 1-phase cell cycle regulation. Nat Rev Mol Cell Biol 2004; 5:355-366
23. Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ. Activation of Rac1, RhoA and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 1995; 15:6443-6453
24. Qiu RG, Chen J, McCormick F, Symons M. A role for Rho in Ras transformation. Proc Natl Acad Sci USA 1995; 92:11781-11785
25. Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF, Der CJ. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene 1995; 10:2289-2296
26. Simon AR, Vikis HG, Stewart S, Fanburg BL, Cochran BH, Guan KL. Regulation of STAT3 by direct binding to the Rac1 GTPase. Science 2000; 290:144-147 (Pubitemid 30752089)
27. Aznar S, Valeron PF, del Rincon SV, Perez LF, Perona R, Lacal JC. Simultaneous tyrosine and serine phosphorylation of STAT3 transcription factor is involved in Rho A GTPase oncogenic transformation. Mol Biol Cell 2001; 12:3282-3294 (Pubitemid 33062979)
28. Faruqi TR, Gomez D, Bustelo XR, Bar-Sagi D, Reich NC. Rac1 mediates STAT3 activation by autocrine IL-6. Proc Natl Acad Sci USA 2001; 98:9014-9019 (Pubitemid 32743861)
29. Benitah SA, Valeron PF, Rui H, Lacal JC. STAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoA. Mol Biol Cell 2003; 14:40-53. (Pubitemid 36106018)
30. Mizejewski GJ. Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev Anticancer Ther 2002; 2:709-735 (Pubitemid 35469493)
31. Gillespie JR, Uversky VN. Structure and function of alpha-fetoprotein: a biophysical overview. Biochim Biophys Acta 2000; 1480:41-56. (Pubitemid 30427384)
32. Pishvaian MJ, Feltes CM, Thompson P, Bussemakers MJ, Schalken JA, Byers SW. Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res 1999; 59:947-952 (Pubitemid 29086753)
33. Braungart E, Schumacher C, Hartmann E, Nekarda H, Becker KF, Hofler H, et al. Functional loss of E-cadherin and cadherin-11 alleles on chromosome 16q22 in colonic cancer. J Pathol 1999; 187:530-534 (Pubitemid 29151993)
34. Heasley LE. Autocrine and paracrine signaling through neuropeptide receptors in human cancer. Oncogene 2001; 20:1563-1569 (Pubitemid 32336844)
35. Caron C, Pivot-Pajot C, van Grunsven LA, Col E, Lestrat C, Rousseaux S, et al. Cdyl: a new transcriptional co-repressor. EMBO Rep 2003; 4:877-882
36. INK4b gene methylation and myelodysplastic syndromes. Leuk Lymphoma 1999; 35:437-443
37. INK4 genes in hematologic malignancies. Leuk Lymphoma 1996; 23:235-245
38. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003; 30:3-14. (Pubitemid 36828623)
39. Timpl R, Sasaki T, Kostka G, Chu ML. Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 2003; 4:479-489 (Pubitemid 36648593)
40. Liu X, Zhao Y, Gao J, Pawlyk B, Starcher B, Spencer JA, et al. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat Genet 2004; 36:178-182 (Pubitemid 38174378)
41. Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 2002; 62:4478-4483 (Pubitemid 34827311)
42. Barker PA, Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis and neurogenetic disease. J Neurosci Res 2002; 67:705-712 (Pubitemid 34226281)
43. Kawaguchi Y, Cooper B, Gannon M, Ray M, MacDonald RJ, Wright CV. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat Genet 2002; 32:128-134 (Pubitemid 34977207)
44. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004; 204:127-143 (Pubitemid 38167717)
45. Deuel TF, Zhang N, Yeh HJ, Silos-Santiago I, Wang ZY. Pleiotrophin: a cytokine with diverse functions and a novel signaling pathway. Arch Biochem Biophys 2002; 397:162-171 (Pubitemid 34852276)
46. Taketo MM. Shutting down Wnt signal-activated cancer. Nat Genet 2004; 36:320-322 (Pubitemid 38437248)
47. Caldwell GM, Jones C, Gensberg K, Jan S, Hardy RG, Byrd P, et al. The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res 2004; 64:883-888 (Pubitemid 38176888)
48. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003; 200:488-499 (Pubitemid 36818249)
49. Lawler J, Detmar M. Tumor progression: the effects of thrombospondin-1 and -2. Int J Biochem Cell Biol 2004; 36:1038-1045
50. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGFbeta in homeostasis and cancer. Nat Rev Cancer 2003; 3:807-821 (Pubitemid 37376979)
51. Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, et al. Overexpression, amplification and androgen regulation of TPD52 in prostate cancer. Cancer Res 2004; 64:3814-3822 (Pubitemid 38697290)
52. Soon LL, Yie TA, Shvarts A, Levine AJ, Su F, Tchou-Wong KM. Overexpression of WISP-1 downregulated motility and invasion of lung cancer cells through inhibition of Rac activation. J Biol Chem 2003; 278:11465-11470 (Pubitemid 36792706)
53. Moon C, Soria JC, Jang SJ, Lee J, Obaidul HM, Sibony M, et al. Involvement of aquaporins in colorectal carcinogenesis. Oncogene 2003; 22:6699-6703
54. Wolf G. Cellular retinol-binding protein functions in the regulation of retinoid metabolism. Nutr Rev 1992; 50:197-199
55. Tsuji K, Feng MA, Wang D. Development of human lymphohematopoiesis defined by CD34 and CD81 expression. Leuk Lymphoma 2002; 43:2269-2273 (Pubitemid 35386149)
56. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000; 1471:43-56.
57. Reimer CL, Borras AM, Kurdistani SK, Garreau JR, Chung M, Aaronson SA, et al. Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells. J Biol Chem 1999; 274:11022-11029 (Pubitemid 129528309)
58. Chen X. Cyclin G: a regulator of the p53-Mdm2 network. Dev Cell 2002; 2:518-519
59. Bieker JJ. Kruppel-like factors: three fingers in many pies. J Biol Chem 2001; 276:34355-34358 (Pubitemid 37384419)
60. Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE, Yang VW. Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene 2004; 23:395-402. (Pubitemid 38174993)
61. Bach LA. Insulin-like growth factor binding protein-6: the "forgotten" binding protein? Horm Metab Res 1999; 31:226-234
62. Sueoka N, Lee HY, Wiehle S, Cristiano RJ, Fang B, Ji L, et al. Insulin-like growth factor binding protein-6 activates programmed cell death in non-small cell lung cancer cells. Oncogene 2000; 19:4432-4436 (Pubitemid 30744373)
63. Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer 2004; 90:561-565 (Pubitemid 38297190)
64. Mercurio AM, Rabinovitz I, Shaw LM. The alpha6beta4 integrin and epithelial cell migration. Curr Opin Cell Biol 2001; 13:541-545 (Pubitemid 32817011)
65. Xin H, Geng Y, Pramanik R, Choubey D. Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival. J Cell Biochem 2003; 88:191-204. (Pubitemid 36015088)
66. Min W, Ghosh S, Lengyel P. The interferon-inducible p202 protein as a modulator of transcription: inhibition of NFkappa B, c-Fos and c-Jun activities. Mol Cell Biol 1996; 16:359-368 (Pubitemid 126506982)
67. Yousef GM, Yacoub GM, Polymeris ME, Popalis C, Soosaipillai A, Diamandis EP. Kallikrein gene downregulation in breast cancer. Br J Cancer 2004; 90:167-172 (Pubitemid 38174957)
68. Kishi T, Grass L, Soosaipillai A, Scorilas A, Harbeck N, Schmalfeldt B, et al. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res 2003; 63:2771-2774 (Pubitemid 36667147)
69. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance and tumor immune escape. J Cell Physiol 2003; 195:346-355 (Pubitemid 36529863)
70. Muminova ZE, Strong TV, Shaw DR. Characterization of human mesothelin transcripts in ovarian and pancreatic cancer. BMC Cancer 2004; 4:19. (Pubitemid 38851354)
71. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelinfamily proteins and diagnosis of mesothelioma. Lancet 2003; 362:1612-1616
72. Bowers AJ, Boylan JF. Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors. Gene 2004; 328:135-142 (Pubitemid 38352890)
73. das Neves L, Duchala CS, Tolentino-Silva F, Haxhiu MA, Colmenares C, Macklin WB, et al. Disruption of the murine nuclear factor I-A gene (Nfia) results in perinatal lethality, hydrocephalus and agenesis of the corpus callosum. Proc Natl Acad Sci USA 1999; 96:11946-11951
74. Lindsay ME, Plafker K, Smith AE, Clurman BE, Macara IG. Npap60/Nup50 is a tristable switch that stimulates importin-alpha:beta-mediated nuclear protein import. Cell 2002; 110:349-360 (Pubitemid 34899383)
75. Chen G, Courey AJ. Groucho/TLE family proteins and transcriptional repression. Gene 2000; 249:1-16. (Pubitemid 30265483)
76. Rice CM. Is CD81 the key to hepatitis C virus entry? Hepatology 1999; 29:990-992
77. Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 1998; 16:89-109. (Pubitemid 28183360)
78. Sapi E. The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp Biol Med (Maywood) 2004; 229:1-11. (Pubitemid 38101673)
79. Lin EY, Gouon-Evans V, Nguyen AV, Pollard JW. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia 2002; 7:147-162 (Pubitemid 38420772)
80. Frank M, Kemler R. Protocadherins. Curr Opin Cell Biol 2002; 14:557-562
81. Brott BK, Sokol SY. Regulation of Wnt/LRP signaling by distinct domains of Dickkopf proteins. Mol Cell Biol 2002; 22:6100-6110 (Pubitemid 34857830)
82. Wu W, Glinka A, Delius H, Niehrs C. Mutual antagonism between dickkopf1 and dickkopf2 regulates Wnt/beta-catenin signalling. Curr Biol 2000; 10:1611-1614 (Pubitemid 32062666)
83. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003; 162:1807-1815 (Pubitemid 36613039)
84. Furukawa T, Yatsuoka T, Youssef EM, Abe T, Yokoyama T, Fukushige S, et al. Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer. Cytogenet Cell Genet 1998; 82:156-159 (Pubitemid 29002456)
85. Zhu Z, Kleeff J, Friess H, Wang L, Zimmermann A, Yarden Y, et al. Epiregulin is Upregulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun 2000; 273:1019-1024 (Pubitemid 30481072)
86. Torring N, Jorgensen PE, Sorensen BS, Nexo E. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGFalpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 2000; 20:91-95
87. Zhou R, Diehl D, Hoeflich A, Lahm H, Wolf E. IGF-binding protein-4: biochemical characteristics and functional consequences. J Endocrinol 2003; 178:177-193 (Pubitemid 37063060)
88. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374:1-20. (Pubitemid 37046923)
89. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 2001; 12:33-40.
90. Kurebayashi J. Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications. Breast Cancer 2000; 7:124-129
91. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1:1356-1370
92. Li X, Eriksson U. Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev 2003; 14:91-98 (Pubitemid 36389523)
93. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 2003; 3:362-374 (Pubitemid 37328856)
94. King LS, Kozono D, Agre P. From structure to disease: the evolving tale of aquaporin biology. Nat Rev Mol Cell Biol 2004; 5:687-698 (Pubitemid 39208179)
95. Lau LF, Lam SC. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 1999; 248:44-57. (Pubitemid 29393928)
96. Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ. WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev 2000; 14:585-595
97. Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, Lee J, et al. WISP genes are members of the connective tissue growth factor family that are upregulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci USA 1998; 95:14717-14722 (Pubitemid 29003696)
98. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4:505-518
99. Klampfer L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 2006; 6:107-121
100. Gowri PM, Ganguly TC, Cao J, Devalaraja MN, Groner B, Vore M. Conversion of threonine 757 to valine enhances Stat5a transactivation potential. J Biol Chem 2001; 276:10485-10491 (Pubitemid 37391963)
101. Wong AH, Durbin JE, Li S, Dever TE, Decker T, Koromilas AE. Enhanced antiviral and antiproliferative properties of a STAT1 mutant unable to interact with the protein kinase PKR. J Biol Chem 2001; 276:13727-13737 (Pubitemid 37391746)
102. nd ed. Cold Spring Harbor, New York, USA: Cold Spring Harbor Laboratory Press 1989.
103. Sauzeau V, Rolli-Derkinderen M, Marionneau C, Loirand G, Pacaud P. RhoA expression is controlled by nitric oxide through cGMP-dependent protein kinase activation. J Biol Chem 2003; 278:9472-9480 (Pubitemid 36800439)
104. Novak JP, Sladek R, Hudson TJ. Characterization of variability in large-scale gene expression data: implications for study design. Genomics 2002; 79:104-113